Table 1 Baseline characteristics of the development set from the Mayo Clinic and the validation set from the Swiss ADPKD study
Class | Total number # (%) | Men/Women(n/n) | Median age (yr) | Median eGFR (ml/min per 1.73 m2) | Median HtTKV (mL/m) | Median follow-up (yr) |
|---|---|---|---|---|---|---|
Mayo Clinic | ||||||
1A | 40 (10.6) | 7/33 | 50 (44–58) | 84 (64–97) | 249 (214–280) | 5 (3–10) |
1B | 88 (23.4) | 23/65 | 46 (36–53) | 78 (62–97) | 433 (322–565) | 6 (3–9) |
1C | 122 (32.4) | 46/76 | 44 (36–50) | 71 (47–98) | 701 (514–1037) | 6 (4–10) |
1D | 77 (20.4) | 40/37 | 41 (34–49) | 60 (36–96) | 1195 (843–1544) | 6 (4–11) |
1E | 49 (13.0) | 28/21 | 36 (29–43) | 46 (26–94) | 1874 (1118–2609) | 5 (3–8) |
Subtotal | 376 (100) | 144/232 | 44 (35–51) | 71 (44–97) | 651 (431–1195) | 6 (4–10) |
Swiss ADPKD | ||||||
1A | 27 (12.6) | 9/18 | 29.43 (24–37) | 86.67 (78–102) | 199.52 (178–232) | 5.19 (1.99–8.35) |
1B | 52 (24.3) | 20/32 | 36.15 (29–46) | 83.84 (72–100) | 343.75 (272–421) | 5.28 (3.13–7.92) |
1C | 60 (28.0) | 35/25 | 35.56 (28–41) | 83.14 (71–92) | 514.31 (407–630) | 4.24 (2.02–8.26) |
1D | 52 (24.3) | 38/14 | 32.48 (28–38) | 79.35 (72–94) | 705.70 (579–910) | 6.25 (2.85–8.95) |
1E | 23 (10.7) | 18/5 | 29.82 (23–35) | 70.30 (56–86) | 1166.50 (920–1425) | 6.93 (3.27–8.53) |
Subtotal | 214 (100) | 120/94 | 34.22 (27–40) | 82.20 (70–95) | 496.58 (317–762) | 5.13 (2.21–8.48) |